| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036965795 |
| P356 | DOI | 10.2165/11310820-000000000-00000 |
| P698 | PubMed publication ID | 19689167 |
| P50 | author | David Taylor | Q55762444 |
| P2093 | author name string | Shubhra Mace | |
| P2860 | cites work | Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial | Q28244389 |
| The positive and negative syndrome scale (PANSS) for schizophrenia | Q28301751 | ||
| A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia | Q33290854 | ||
| Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride | Q33959951 | ||
| Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride | Q34011162 | ||
| Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia | Q34507860 | ||
| Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia | Q34560981 | ||
| Quetiapine: dose-response relationship in schizophrenia | Q34585989 | ||
| Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study | Q34589922 | ||
| Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study | Q34594237 | ||
| Dose response and dose equivalence of antipsychotics | Q35810536 | ||
| Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo | Q38394215 | ||
| Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. | Q38399645 | ||
| Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 | ||
| Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. | Q44167467 | ||
| Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder | Q44513113 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. | Q44662788 | ||
| Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. | Q45958125 | ||
| Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia | Q46416379 | ||
| Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 | ||
| Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study | Q46701458 | ||
| Aripiprazole's receptor pharmacology and extrapyramidal side effects | Q46721202 | ||
| Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | Q46886132 | ||
| Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice | Q46894410 | ||
| A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. | Q47208132 | ||
| Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs | Q48161863 | ||
| Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. | Q55044398 | ||
| Datapoints: The Ups and Downs of Dosing Second-Generation Antipsychotics | Q56791120 | ||
| Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials | Q72691613 | ||
| The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia | Q80200256 | ||
| Neuroleptic-induced deficit syndrome: old problem, new challenge | Q83365216 | ||
| P433 | issue | 9 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 773-780 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder | |
| P478 | volume | 23 |
| Q33618959 | A case of aripiprazole induced tardive dyskinesia in a neuroleptic-naïve patient with two years of follow up. |
| Q37058653 | A potential mechanism underlying atypical antipsychotics-induced lipid disturbances |
| Q48512330 | Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia |
| Q37973222 | Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents |
| Q48234174 | Aripiprazole Increases the PKA Signalling and Expression of the GABAA Receptor and CREB1 in the Nucleus Accumbens of Rats |
| Q36846918 | Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats |
| Q24200753 | Aripiprazole dose for schizophrenia |
| Q37111054 | Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats |
| Q33662847 | Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea |
| Q37155297 | Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone |
| Q46703897 | Intramuscular aripiprazole in the acute management of psychomotor agitation |
| Q37078959 | Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports |
| Q35044176 | Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme |
| Q64330025 | TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel |
Search more.